Douglas Scherr

Last updated

Douglas S. Scherr, M.D. (born January 7, 1967) is an American surgeon and specialist in Urologic Oncology. He is currently the Clinical Director of Urologic Oncology at Weill Cornell Medicine. [1] He also holds an appointment at the Rockefeller University as a Visiting Associate Physician. Scherr was the first physician at Cornell to perform a robotic prostatectomy as well as a robotic cystectomy. [2] [3]

Contents

Background

A native of New York, Scherr studied at Cornell University and received an undergraduate degree in government. After University, Dr. Scherr spent a year abroad in Shenyang, China, after which he attended medical school at the George Washington University School of Medicine . Subsequently, he completed a 6-year residency in Urology at the New York-Presbyterian Hospital and a Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center for two years. He is married to Jennifer Scherr and they have three children.

Areas of focus

Scherr specializes in treating urologic malignancies. His focus is on the treatment of prostate cancer, bladder cancer, kidney cancer, testicular cancer, and genitourinary and retroperitoneal sarcomas. He performs robotic assisted removal of bladders with total bladder reconstructions, along with colleague Dr. Shahrokh Shariat.

He sits on several advisory boards in companies involved in urologic technology development. He has been influential in the ergonomics of robotic technology. He has been active in the development of optical coherence tomography and its application to urologic imaging.

Also active in the Laboratory of Urologic Oncology, Scherr has been instrumental in defining the hormonal regulation of bladder cancer and is currently developing a novel class of compounds that utilize the innate immune system to fight urologic tumors. He is working on the development of a non-invasive means to assess human tissue at the microscopic level. To this end, he has patented and developed the concept of “multiphoton endoscopy” which utilizes high speed laser energy to create high quality microscopic images of human tissue. This breakthrough has vast applications in cystoscopy, colonoscopy and bronchoscopy.

Board certification

American Board of Urology (February, 2003)

Professional organizations

Diplomate, American Board of Urology
Member, Society of Urologic Oncology
Founding Member, Executive Committee, Young Urologic Oncology Society
Member, Society for Basic Urological Research
Member, American Urological Association
Member, New York Section of AUA, Co-chair of Valentine Essay Meeting
Member, Society of University Urologists
Member, American Medical Association
Lecturer, American Austrian Foundation
Member, Cancer and Leukemia Group B (CALGB), GU Core
Member, American Association for Cancer Research (AACR)

Professional honors/awards

  1. William Beaumont Medical Research Honor Society First Prize for Best Original Medical Essay, The William Shafirt Award, The George Washington University School of Medicine. “A crisis of unknown proportion: An empirical analysis of the American medical malpractice system.” 1994
  2. First Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “BCL-2 and P53 expression in clinically localized prostate cancer as predictive markers for the response to external beam radiotherapy.” 1998
  3. First Prize for Clinical Investigation, Society of University Urology Residents, Annual Chief Resident Meeting, Marietta, Georgia. “Anti-androgen therapy for prostate cancer and the prevention of osteoporosis: The role of DES.” 2000
  4. Second Prize for Clinical Investigation, Ferdinand C. Valentine Urology Residents Essay Meeting, “Collagen Type I Crosslinked N-Telopeptide as a urinary marker for osteoporosis in prostate cancer: The role of Diethylstilbesterol (DES).” 2000
  5. Pfizer, Scholars in Urology Award, Awarded for advancing the scientific and clinical field of urology. 2000
  6. Ferdinand C. Valentine Fellowship for Research in Urology. The New York Academy of Medicine. 2001–2002. Syndecan-1 expression in prostate cancer and the role of p27 in primary prostate epithelial cell transformation.
  7. T32 Research Training Grant. Memorial Sloan Kettering Cancer Center. 2000–2002.
  8. Edwin Beer Research Award. NY Academy of Medicine. Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2005-2007
  9. Career Development Award. Kidney Urology Foundation of America. The role of the Pim-1 Oncoprotein in Prostate Carcinogenesis. 2004-2005
  10. Best Video Award. Society of Laparoscopic Surgery. Oncological Outcomes of Robotic Cystectomy. San Francisco, CA August, 2007.

Publications

  1. Raman, JD; Sosa, RE; Vaughan Ed, Jr; Scherr, DS (2007). "Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma". Urology. 69 (2): 251–4. doi:10.1016/j.urology.2006.09.065. PMID   17320658.
  2. Smith, EB; Schwartz, M; Kawamoto, H; You, X; Hwang, D; Liu, H; Scherr, DS (2007). "Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder". The Journal of Urology. 177 (6): 2347–51. doi:10.1016/j.juro.2007.01.112. PMID   17509356.
  3. Barocas, DA; Mathew, S; Delpizzo, JJ; Vaughan Ed, ED; Sosa, RE; Fine, RG; Akhtar, M; Scherr, DS (2007). "Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle-biopsy specimen". BJU International. 99 (2): 290–5. doi:10.1111/j.1464-410X.2006.06607.x. PMID   17092279. S2CID   27845456.
  4. Raman, JD; Dong, S; Levinson, A; Samadi, D; Scherr, DS (2007). "Robotic Radical Prostatectomy: Operative Technique, Outcomes, and Learning Curve". JSLS. 11 (1): 1–7. PMC   3015817 . PMID   17651548.
  5. Raman, JD; Scherr, DS (2007). "Management of patients with upper urinary tract transitional cell carcinoma". Nature Clinical Practice Urology. 4 (8): 432–43. doi:10.1038/ncpuro0875. PMID   17673914. S2CID   21351473.
  6. Wang, GJ; Barocas, DA; Raman, JD; Scherr, DS (2008). "Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy". BJU International. 101 (1): 89–93. doi:10.1111/j.1464-410X.2007.07212.x. PMID   17888044. S2CID   10233606.
  7. Liu, H; Schwartz, MJ; Hwang, DH; Scherr, DS (2008). "Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma". BJU International. 101 (7): 894–901. doi:10.1111/j.1464-410X.2008.07459.x. PMID   18241249. S2CID   205538510.
  8. Schwartz, MJ; Hwang, DH; Hung, AJ; Han, J; Mcclain, JW; Shemtov, MM; Te, AE; Sosa, RE; et al. (2008). "Negative influence of changing biopsy practice patterns on the predictive value of prostate-specific antigen for cancer detection on prostate biopsy". Cancer. 112 (8): 1718–25. doi: 10.1002/cncr.23353 . PMID   18330908.
  9. Richstone, L; Bianco, FJ; Shah, HH; Kattan, MW; Eastham, JA; Scardino, PT; Scherr, DS (2008). "Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram". BJU International. 101 (5): 541–6. doi: 10.1111/j.1464-410X.2007.07410.x . PMID   18257855.
  10. Seandel, M; James, D; Shmelkov, SV; Falciatori, I; Kim, J; Chavala, S; Scherr, DS; Zhang, F; et al. (2007). "Generation of functional multipotent adult stem cells from GPR125+ germline progenitors". Nature. 449 (7160): 346–50. doi:10.1038/nature06129. PMC   2935199 . PMID   17882221.
  11. Barocas, DA; Rabbani, F; Scherr, DS; Vaughan Ed, ED (2006). "A population-based study of renal cell carcinoma and prostate cancer in the same patients". BJU International. 97 (1): 33–6. doi:10.1111/j.1464-410X.2005.05880.x. PMID   16336324. S2CID   10616104.
  12. Barocas, DA; Rohan, SM; Kao, J; Gurevich, RD; Del Pizzo, JJ; Vaughan Ed, Jr; Akhtar, M; Chen, YT; Scherr, DS (2006). "Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis". The Journal of Urology. 176 (5): 1957–62. doi:10.1016/j.juro.2006.07.038. PMID   17070218.
  13. Raman, JD; Palese, MA; Ng, CK; Boorjian, SA; Scherr, DS; Del Pizzo, JJ; Sosa, RE (2006). "Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma". JSLS. 10 (4): 432–8. PMC   3015762 . PMID   17575752.
  14. Shelton, JB; Barocas, DA; Conway, F; Hart, K; Nelson, K; Richstone, L; Gonzalez, RR; Raman, JD; Scherr, DS (2005). "Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies". Urology. 65 (5): 931–6. doi:10.1016/j.urology.2004.11.047. PMID   15882726.
  15. Boorjian, S; Ng, C; Munver, R; Palese, MA; Vaughan Ed, Jr; Sosa, RE; Del Pizzo, JJ; Scherr, DS (2005). "Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma". Urology. 66 (2): 283–7. doi:10.1016/j.urology.2005.02.022. PMID   16098357.
  16. Pittsjr, W; Scherr, D (2005). "Unified theory of prostate cancer: the role of steroid 5 alpha reductase and steroid aromatase". Urology. 66 (3): 11–12. doi:10.1016/j.urology.2005.06.039.
  17. Barocas, DA; Kawamoto, H; Dreizin, DF; Howard, ME; Choi, J; Pitts, WR; You, X; Tickoo, SK; et al. (2005). "Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome". Urology. 66 (5): 1134–9. doi:10.1016/j.urology.2005.06.079. PMID   16286153.
  18. Raman, JD; Mongan, NP; Tickoo, SK; Boorjian, SA; Scherr, DS; Gudas, LJ (2005). "Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder". Clinical Cancer Research. 11 (24 Pt 1): 8570–6. doi: 10.1158/1078-0432.CCR-05-1047 . PMID   16361539.
  19. Raman, JD; Ng, CK; Boorjian, SA; Vaughan Ed, ED; Sosa, RE; Scherr, DS (2005). "Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology". BJU International. 96 (7): 1031–5. doi:10.1111/j.1464-410X.2005.05804.x. PMID   16225523. S2CID   26096624.
  20. Raman, JD; Mongan, NP; Liu, L; Tickoo, SK; Nanus, DM; Scherr, DS; Gudas, LJ (2006). "Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma". Carcinogenesis. 27 (3): 499–507. doi: 10.1093/carcin/bgi299 . PMID   16344273.
  21. Boorjian, S; Scherr, DS; Mongan, NP; Zhuang, Y; Nanus, DM; Gudas, LJ (2005). "Retinoid receptor mRNA expression profiles in human bladder cancer specimens". International Journal of Oncology. 26 (4): 1041–8. doi:10.3892/ijo.26.4.1041. PMID   15754000.
  22. Boorjian, S; Ng, C; Munver, R; Palese, MA; Sosa, RE; Vaughan, ED; Del Pizzo, JJ; Scherr, DS (2004). "Abnormal selective cytology results predict recurrence of upper-tract transitional-cell carcinoma treated with ureteroscopic laser ablation". Journal of Endourology. 18 (9): 912–6. doi:10.1089/end.2004.18.912. PMID   15659932.
  23. Richstone, L; Scherr, DS; Reuter, VR; Snyder, ME; Rabbani, F; Kattan, MW; Russo, P (2004). "Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival". The Journal of Urology. 171 (2 Pt 1): 615–20. doi:10.1097/01.ju.0000106955.19813.f6. PMID   14713772.
  24. Boorjian, S; Tickoo, SK; Mongan, NP; Yu, H; Bok, D; Rando, RR; Nanus, DM; Scherr, DS; Gudas, LJ (2004). "Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer". Clinical Cancer Research. 10 (10): 3429–37. doi: 10.1158/1078-0432.CCR-03-0756 . PMID   15161698.
  25. Boorjian, S; Ugras, S; Mongan, NP; Gudas, LJ; You, X; Tickoo, SK; Scherr, DS (2004). "Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer". Urology. 64 (2): 383–8. doi:10.1016/j.urology.2004.03.025. PMID   15302512.
  26. Chen, David Y. T.; Sosa, RE; Scherr, DS (2004). "Treatment of adrenocortical carcinoma: Contemporary outcomes". Current Urology Reports. 5 (1): 65–72. doi:10.1007/s11934-004-0014-x. PMID   14733841. S2CID   41696275.
  27. Scherr, D; Swindle, PW; Scardino, PT; National Comprehensive Cancer Network (2003). "National Comprehensive Cancer Network guidelines for the management of prostate cancer". Urology. 61 (2 Suppl 1): 14–24. doi:10.1016/S0090-4295(02)02395-6. PMID   12667883.
  28. Scherr, Douglas S.; Ng, C; Munver, R; Sosa, RE; Vaughan Jr, ED; Del Pizzo, J (2003). "Practice patterns among urologic surgeons treating localized renal cell carcinoma in the laparoscopic age: technology versus oncology". Urology. 62 (6): 1007–11. doi:10.1016/S0090-4295(03)00773-8. PMID   14665345.
  29. Scherr, DS; Pitts Wr, Jr (2003). "The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer". The Journal of Urology. 170 (5): 1703–8. doi:10.1097/01.ju.0000077558.48257.3d. PMID   14532759.
  30. Knudsen, Beatrice S; Gmyrek, GA; Inra, J; Scherr, DS; Vaughan, ED; Nanus, DM; Kattan, MW; Gerald, WL; Vande Woude, GF (2002). "High expression of the Met receptor in prostate cancer metastasis to bone☆". Urology. 60 (6): 1113–7. doi:10.1016/S0090-4295(02)01954-4. PMID   12475693.
  31. Scherr, D; Pittsjr, WR; Vaughanjr, ED (2002). "Diethylstilbesterol Revisited: Androgen Deprivation, Osteoporosis and Prostate Cancer". The Journal of Urology. 167 (2 Pt 1): 535–8. doi:10.1016/S0022-5347(01)69080-3. PMID   11792913.
  32. Scherr, DS; Eastham, J; Ohori, M; Scardino, PT (2002). "Prostate biopsy techniques and indications: when, where, and how?". Seminars in Urologic Oncology. 20 (1): 18–31. doi:10.1053/suro.2002.30395. PMID   11828354.
  33. Chen, A; Scherr, D; Eid, JF (2000). "Renal Transplantation After in Vivo Excision of an Angiomyolipoma from a Living Unrelated Kidney Donor". The Journal of Urology. 163 (6): 1859. doi:10.1016/S0022-5347(05)67561-1. PMID   10799200.
  34. "ERRATA". The Journal of Urology. 162 (2): 503. 1999. doi:10.1016/S0022-5347(05)68615-6.
  35. Scherr, DS; Vaughan Ed, Jr; Wei, J; Chung, M; Felsen, D; Allbright, R; Knudsen, BS (1999). "BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy". The Journal of Urology. 162 (1): 12–6, discussion 16–7. doi:10.1097/00005392-199907000-00003. PMID   10379729.
  36. Scherr, D; Goldstein, M (1999). "Comparison of bilateral versus unilateral varicocelectomy in men with palpable bilateral varicoceles". The Journal of Urology. 162 (1): 85–8. doi:10.1097/00005392-199907000-00021. PMID   10379746.
  37. Scherr, D; Poppas, DP (1998). "Laser Tissue Welding". Urologic Clinics of North America. 25 (1): 123–35. doi:10.1016/S0094-0143(05)70439-0. PMID   9529543.
  38. Poppas, DP; Scherr, DS (1998). "Laser tissue welding: a urological surgeon's perspective". Haemophilia. 4 (4): 456–62. doi:10.1046/j.1365-2516.1998.440456.x. PMID   9873775. S2CID   1078110.
  39. Schultz, PK; Herr, HW; Zhang, ZF; Bajorin, DF; Seidman, A; Sarkis, A; Fair, WR; Scherr, D; et al. (1994). "Neoadjuvant Chemotherapy for Invasive Bladder Cancer: Prognostic Factors for Survival of Patients Treated with M-VAC with Five-Year Follow-Up". Journal of Clinical Oncology. 12 (7): 1394–1401. doi:10.1200/JCO.1994.12.7.1394. PMID   8021730.

Related Research Articles

<span class="mw-page-title-main">Urology</span> Medical specialty

Urology, also known as genitourinary surgery, is the branch of medicine that focuses on surgical and medical diseases of the urinary-tract system and the reproductive organs. Organs under the domain of urology include the kidneys, adrenal glands, ureters, urinary bladder, urethra, and the male reproductive organs.

<span class="mw-page-title-main">Prostate cancer</span> Male reproductive organ cancer

Prostate cancer is cancer of the prostate. Prostate cancer is the second most common cancerous tumor worldwide and is the fifth leading cause of cancer-related mortality among men. The prostate is a gland in the male reproductive system that surrounds the urethra just below the bladder. It is located in the hypogastric region of the abdomen. To give an idea of where it is located, the bladder is superior to the prostate gland as shown in the image The rectum is posterior in perspective to the prostate gland and the ischial tuberosity of the pelvic bone is inferior. Only those who have male reproductive organs are able to get prostate cancer. Most prostate cancers are slow growing. Cancerous cells may spread to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, symptoms include pain or difficulty urinating, blood in the urine, or pain in the pelvis or back. Benign prostatic hyperplasia may produce similar symptoms. Other late symptoms include fatigue, due to low levels of red blood cells.

<span class="mw-page-title-main">Benign prostatic hyperplasia</span> Noncancerous increase in size of the prostate gland

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

<span class="mw-page-title-main">Bladder cancer</span> Urinary system cancer that begins in the urinary bladder

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.

<span class="mw-page-title-main">Prostate-specific antigen</span> Mammalian protein found in humans

Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland.

<span class="mw-page-title-main">Hematuria</span> Medical condition

Hematuria or haematuria is defined as the presence of blood or red blood cells in the urine. “Gross hematuria” occurs when urine appears red, brown, or tea-colored due to the presence of blood. Hematuria may also be subtle and only detectable with a microscope or laboratory test. Blood that enters and mixes with the urine can come from any location within the urinary system, including the kidney, ureter, urinary bladder, urethra, and in men, the prostate. Common causes of hematuria include urinary tract infection (UTI), kidney stones, viral illness, trauma, bladder cancer, and exercise. These causes are grouped into glomerular and non-glomerular causes, depending on the involvement of the glomerulus of the kidney. But not all red urine is hematuria. Other substances such as certain medications and foods can cause urine to appear red. Menstruation in women may also cause the appearance of hematuria and may result in a positive urine dipstick test for hematuria. A urine dipstick test may also give an incorrect positive result for hematuria if there are other substances in the urine such as myoglobin, a protein excreted into urine during rhabdomyolysis. A positive urine dipstick test should be confirmed with microscopy, where hematuria is defined by three of more red blood cells per high power field. When hematuria is detected, a thorough history and physical examination with appropriate further evaluation can help determine the underlying cause.

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

<span class="mw-page-title-main">Sentinel lymph node</span> First lymph node to receive drainage from a primary tumor

The sentinel lymph node is the hypothetical first lymph node or group of nodes draining a cancer. In case of established cancerous dissemination it is postulated that the sentinel lymph nodes are the target organs primarily reached by metastasizing cancer cells from the tumor.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It accounts for 95% of bladder cancer cases.

<span class="mw-page-title-main">Urachal cancer</span> Medical condition

Urachal cancer is a very rare type of cancer arising from the urachus or its remnants. The disease might arise from metaplasic glandular epithelium or embryonic epithelial remnants originating from the cloaca region.

Lower urinary tract symptoms (LUTS) refer to a group of clinical symptoms involving the bladder, urinary sphincter, urethra and, in men, the prostate. The term is more commonly applied to men—over 40% of older men are afected—but lower urinary tract symptoms also affect women. The condition is also termed prostatism in men, but LUTS is preferred.

<span class="mw-page-title-main">Chronic prostatitis/chronic pelvic pain syndrome</span> Medical condition

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), previously known as chronic nonbacterial prostatitis, is long-term pelvic pain and lower urinary tract symptoms (LUTS) without evidence of a bacterial infection. It affects about 2–6% of men. Together with IC/BPS, it makes up urologic chronic pelvic pain syndrome (UCPPS).

<span class="mw-page-title-main">Mani Menon</span>

Mani Menon, born 9 July 1948 in Trichur, India, is an American surgeon whose pioneering work has helped to lay the foundation for modern Robotic Cancer Surgery. He is the founding director and the Raj and Padma Vattikuti Distinguished Chair of the Vattikuti Urology Institute at the Henry Ford Hospital in Detroit, MI, where he established the first cancer-oriented robotics program in the world. Menon is widely regarded for his role in the development of robotic surgery techniques for the treatment of patients with prostate, kidney, and bladder cancers, as well as for the development of robotic kidney transplantation.
Menon is the recipient of the Gold Cystoscope award, Hugh Hampton Young award, the Keyes Medal, the prestigious B.C. Roy award.

Simon J. Hall, M.D., is the Associate Professor and Kyung Hyun Kim, M.D. Chair of Urology and Assistant Professor, Department of Gene and Cell Medicine at The Mount Sinai School of Medicine, as well as the Director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center, both in New York City.

<span class="mw-page-title-main">Michael Palese</span>

Dr. Michael A. Palese, is an American urologist specializing in robotic, laparoscopic and endoscopic surgery, with a special emphasis on robotic surgeries relating to kidney cancer and kidney stone disease.

Mark S. Soloway is a leading authority in urologic cancer, researcher, former departmental Chair, medical professor and invitational lecturer. He served as Chairman of the University of Miami Miller School of Medicine Department of Urology and is currently a Professor at the Miller School of Medicine. Born in Cleveland, Soloway received his B.Sc. from Northwestern University in Chicago (1961–1964). He completed his M.D. and residency at Case Western Reserve University School of Medicine in Cleveland, Ohio (1964–1970). He completed a fellowship at the National Cancer Institute of the National Institute of Health in Bethesda, MD (1970–1972). Soloway has received numerous awards for his work as a researcher and teacher, These awards are American Urological Association's Gold Cystoscope award, Mosby Scholarship for Scholastic Excellence award (1967), North Central Section of American Urological Association Traveling Fellowship award (1972) and many others. These are outstanding achievements for an individual who has contributed most to the field of urology within ten years of completion of his residency program” (1984).

Cora Sternberg is an American medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, serving as a member of the Genitourinary (GU) Oncology Program. Dr. Sternberg facilitates the continued growth and development of clinical and translational research programs in GU malignancies, with a particular emphasis on expanding the overall research portfolio. As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network, including Lower Manhattan, Brooklyn and Queens.

<span class="mw-page-title-main">Prokar Dasgupta</span>

Prokar Dasgupta FRCS(Urol), FEBU is an Indian surgeon and academic who is professor of surgery at the surgical academy at King's Health Partners, London, UK. Since 2002, he has been consultant urologist to Guy's Hospital, and in 2009 became the first professor of robotic surgery and urology at King's, and subsequently the chairman of the King's College-Vattikuti Institute of Robotic Surgery.

Dipen J. Parekh is Chief Operating Officer at the University of Miami Health System, Chairman of Urology and the Dr. Victor Politano Endowed Chair in Clinical Urology at the Miller School of Medicine at University of Miami in Miami. He also serves as the Director of Robotic surgery at the University of Miami Health System. In 2012, he was awarded the American Urological Association Gold Cystoscope Award for his excellence in "establishing programs in urologic oncology and robotic surgery and outstanding contributions in transformative research".

Gaetano Ciancio is an Italian American surgeon at the University of Miami who specializes in kidney transplant. He is the chief medical and academic officer of the Miami Transplant Institute and the director of its Kidney & Kidney-Pancreas Programs. His most significant contributions to medicine are related to surgically treating kidney cancer once it has spread to the inferior vena cava and in optimizing the immunosuppression protocol after kidney transplant.

References

  1. "Dr. Douglas Scherr | SPORE in Prostate Cancer". prostatespore.weill.cornell.edu. Retrieved 2022-10-20.
  2. "Robotic Surgery Extends Benefits to Bladder Cancer Patients at NewYork-Presbyterian/Weill Cornell". WCM Newsroom. Retrieved 2022-10-20.
  3. "Douglas S. Scherr, M.D." What's New in GU?. 2016-06-30. Retrieved 2022-10-20.